An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection. However, large numbers of them are not even aware of their infection as they have not yet been tested and diagnosed.

In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.

People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.

To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.

In order to maximise the benefits of treatment for HIV or viral hepatitis, it is critical to test and diagnose people as soon as possible in the course of the infection. ECDC supports this objective of European Testing Week.

In 2017, the majority (58%) of the almost 27 000 newly reported hepatitis B cases in the European Union and European Economic Area were classified as chronic infections. This follows a consistent upward trend in reported chronic hepatitis B cases since 2008.

Targeted testing is an essential element of any strategy to eliminate viral hepatitis across the countries in the European Union and European Economic Area. Some preliminary monitoring results on the response to hepatitis B and C presented around World Hepatitis Day show that diagnosing chronic infections is still a challenge in the EU/EEA.

On the way towards the Sustainable Development Goal (SDG) for health, Europe has one important battle to take on: reducing the proportion of those living with undiagnosed HIV and viral hepatitis. Current status in the EU/EEA: one in seven people living with HIV are unaware of their infection, up to four out of 5 people living with hepatitis B and three out of four people with hepatitis C infection have not yet been diagnosed.

The first report monitoring the progress towards the elimination of hepatitis B and C across European Union (EU) and European Economic Area (EEA) countries has been published by ECDC.